Publication | Closed Access

Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials

RheumatologyClinical TrialsClinical DermatologyDermatologyMedicineChronic Spontaneous UrticariaClinical AllergyPhase 3